Ledikast 90mg Tablet (Ledipasvir 90mg)

Ledikast 90mg Tablet (Ledipasvir) — Product Identity Requires Confirmation contains Ledipasvir 90mg as supplied by user; confirm whether carton also contains sofosbuvir 400mg. Ledipasvir is an antiviral component used in combination regimens; ledipasvir alone is not an established complete HCV treatment.

Ledipasvir inhibits HCV NS5A, disrupting replication-complex activity and virion assembly. Before treatment, assess HCV RNA, prior therapy, cirrhosis status, hepatitis B markers, other medicines and relevant liver and kidney tests. Cure is generally assessed by undetectable HCV RNA at least 12 weeks after completion (SVR12). Viral clearance does not remove the need for liver cancer surveillance in patients with cirrhosis. UNVERIFIED COMPOSITION: user supplied ledipasvir only. The exact commercial product must be checked before final publication; do not silently add sofosbuvir.

Ledipasvir is an antiviral component used in combination regimens; ledipasvir alone is not an established complete HCV treatment. Treatment selection is based on HCV genotype where relevant, cirrhosis stage, prior antiviral exposure, coinfections and potential drug interactions. Before Ledipasvir treatment, assess HCV RNA, prior therapy, cirrhosis status, hepatitis B markers, other medicines and relevant liver and kidney tests. Cure is generally assessed by undetectable HCV RNA at least 12 weeks after completion (SVR12). Viral clearance does not remove the need for liver cancer surveillance in patients with cirrhosis.

Ledikast 90mg Tablet is made up of ledipasvir, an antiviral drug used to fight specific cases of hepatitis C virus (HCV). This is because the tablet prevents replication of the virus in the body by interfering with the NS5A viral protein that the hepatitis C virus uses to reproduce and propagate. Through interference with the viral protein, Ledikast enables reduction in the amount of hepatitis C virus in the body. Ledikast is normally used in combination with another antiviral drug. This will depend on the type of hepatitis C virus and the health state of the patient. Ledipasvir inhibits HCV NS5A, disrupting replication-complex activity and virion assembly.

ION trials support ledipasvir PLUS sofosbuvir, not ledipasvir monotherapy or an unverified Ledikast formulation. SVR12 is a standard efficacy endpoint in HCV studies; rates cannot be transferred to different genotypes, regimens or cirrhosis groups without qualification.

Adverse-effect profile for ledipasvir alone cannot be substituted from combination trials; ledipasvir/sofosbuvir trials commonly reported fatigue and headache. Side effects may change when additional medicines are included. Discuss persistent symptoms with the treating clinician.

Follow the exact manufacturer instructions for this product and prescribed regimen. Do not double doses. Contact the treating team promptly if a dose is missed or a course is interrupted; the correct response varies between daily direct-acting antivirals and weekly peginterferon injection.

Verify composition before clinical publication; for actual HCV treatment assess HCV RNA, HBV and liver status. Confirm Ledipasvir treatment response with HCV RNA at least 12 weeks after the final dose.

• Molecule/regimen prescribing information: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f4ec77e4-bae8-4db0-b3d5-bde09c5fa075​
  
• AASLD-IDSA HCV Guidance: https://www.hcvguidelines.org/​
  
• WHO hepatitis C guidance: https://www.who.int/health-topics/hepatitis​
  
• ScienceDirect. Hepatitis C treatment. https://www.sciencedirect.com/topics/medicine-and-dentistry/ledipasvir​
  
• Medical information only. Individual treatment and dose selection require specialist assessment. https://cdn.who.int/media/docs/default-source/food-safety/publications/chapter5-dose-response.pdf​